IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CURIGLIANO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15806
NA - Nord America 14452
AS - Asia 8096
SA - Sud America 375
OC - Oceania 300
AF - Africa 156
Continente sconosciuto - Info sul continente non disponibili 62
Totale 39247
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13781
GB - Regno Unito 5914
CN - Cina 4632
IT - Italia 2486
SE - Svezia 2030
DE - Germania 1113
IE - Irlanda 1006
FR - Francia 886
JP - Giappone 739
IN - India 558
CA - Canada 505
ES - Italia 399
KR - Corea 389
TR - Turchia 339
VN - Vietnam 291
HK - Hong Kong 274
AU - Australia 258
NL - Olanda 251
BE - Belgio 200
CH - Svizzera 181
TW - Taiwan 179
UA - Ucraina 178
RU - Federazione Russa 171
ID - Indonesia 155
BR - Brasile 152
DK - Danimarca 142
MX - Messico 139
PL - Polonia 126
FI - Finlandia 102
GR - Grecia 101
AT - Austria 90
EU - Europa 90
NO - Norvegia 83
SG - Singapore 78
TH - Thailandia 77
PT - Portogallo 76
RO - Romania 76
IL - Israele 75
CO - Colombia 69
IR - Iran 68
AR - Argentina 59
PH - Filippine 53
NZ - Nuova Zelanda 40
MY - Malesia 39
CL - Cile 37
PE - Perù 34
CZ - Repubblica Ceca 31
ZA - Sudafrica 30
HR - Croazia 29
HU - Ungheria 29
KE - Kenya 27
PK - Pakistan 27
EG - Egitto 26
AP - ???statistics.table.value.countryCode.AP??? 25
BG - Bulgaria 22
AE - Emirati Arabi Uniti 20
TN - Tunisia 18
LB - Libano 15
JO - Giordania 14
RS - Serbia 14
SK - Slovacchia (Repubblica Slovacca) 14
EC - Ecuador 12
MA - Marocco 12
A2 - ???statistics.table.value.countryCode.A2??? 10
AM - Armenia 10
SA - Arabia Saudita 10
LT - Lituania 9
SC - Seychelles 9
UY - Uruguay 9
CY - Cipro 8
BA - Bosnia-Erzegovina 7
CR - Costa Rica 6
IQ - Iraq 6
KZ - Kazakistan 6
NG - Nigeria 6
SI - Slovenia 6
BY - Bielorussia 5
CU - Cuba 5
DZ - Algeria 5
LU - Lussemburgo 5
MT - Malta 5
MV - Maldive 5
UZ - Uzbekistan 5
EE - Estonia 4
GH - Ghana 4
GT - Guatemala 4
LY - Libia 4
MO - Macao, regione amministrativa speciale della Cina 4
SD - Sudan 4
UG - Uganda 4
BD - Bangladesh 3
GE - Georgia 3
IS - Islanda 3
MD - Moldavia 3
ME - Montenegro 3
MK - Macedonia 3
PA - Panama 3
QA - Qatar 3
DO - Repubblica Dominicana 2
FJ - Figi 2
Totale 39279
Salva come PNG Salva come JPEG
Città #
Southend 5114
Chandler 1458
Fairfield 1241
Milan 1061
Princeton 981
Dublin 977
Houston 831
Wilmington 731
Redwood City 662
Seattle 639
Beijing 603
Woodbridge 547
Ashburn 532
Ann Arbor 428
Nanjing 425
Cambridge 421
Des Moines 351
Dearborn 325
Shanghai 313
Xian 313
Hangzhou 272
Shenyang 222
Guangzhou 216
Tokyo 203
Toronto 193
Jinan 181
Seoul 170
Berlin 156
Central District 142
London 131
Redmond 131
San Diego 129
Phoenix 128
Taipei 114
Changsha 113
Nanchang 113
Boardman 106
Hebei 97
Andover 94
Brussels 94
Zhengzhou 94
New York 93
Duncan 90
Dong Ket 87
Tianjin 86
Chengdu 82
Mountain View 80
Grafing 76
Istanbul 76
Jacksonville 75
Munich 68
Wuhan 67
Ottawa 66
Madrid 64
Central 59
Chicago 58
Rome 58
Silver Spring 58
Paris 57
Fuzhou 53
Barcelona 51
Kunming 51
Buffalo 50
San Francisco 48
Boston 46
Hefei 46
Athens 45
Sydney 45
Bogotá 43
Jiaxing 42
Amsterdam 40
Sakarya 39
Upper Marlboro 39
Rho 38
São Paulo 38
Haikou 36
Hanover 36
Los Angeles 36
Somerville 36
Ankara 35
Norwalk 34
Taiyuan 34
Vienna 34
Lanzhou 33
Turin 32
Fremont 31
Sunnyvale 31
Bologna 30
Ningbo 30
Changchun 29
Mumbai 29
Oslo 29
Taizhou 28
Florence 27
Harbin 27
Jakarta 27
Philadelphia 27
Singapore 27
Falls Church 26
Lima 26
Totale 23836
Salva come PNG Salva come JPEG
Nome #
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1345
Cetuximab for treating non-small cell lung cancer 1245
Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 1133
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) 1132
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial 1021
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases 820
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 627
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan 592
Ribociclib plus letrozole in early breast cancer : a presurgical, window-of-opportunity study 544
Entinostat for the treatment of breast cancer 470
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) 469
Association of Breast Cancer Irradiation With Cardiac Toxic Effects : A Narrative Review 388
Vaccine immunotherapy in breast cancer treatment: Promising, but still early 358
Progresses toward precision medicine in RET-altered solid tumors 331
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative 306
Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors 293
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients with Cancer: A Review 287
Report on the status of women occupying leadership roles in oncology 285
Gender-related challenges facing oncologists: The results of the ESMO Women for Oncology Committee survey 261
Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients 253
De-escalating and escalating treatments for early-stage breast cancer : the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 253
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer 252
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 249
Biologic therapy for advanced breast cancer : recent advances and future directions 241
Defining the immunogram of breast cancer: a focus on clinical trials 229
Margetuximab for the treatment of HER2-positive metastatic breast cancer 223
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆ 219
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 211
Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study 207
Recent advances in triple negative breast cancer: the immunotherapy era 200
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment 199
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) 197
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) 189
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 185
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis 184
Gemcitabine-induced systemic capillary leak syndrome 181
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer 179
Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: A comparative study with cisplatin 174
Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer 174
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer 170
Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic 163
Managing side effects of immune checkpoint inhibitors in breast cancer 162
New approaches for improving outcomes in breast cancer in Europe 161
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis 158
Tailoring therapies-improving the management of early breast cancer : St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 155
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 154
Expression of tumor-associated antigens in breast cancer subtypes 150
Alga : a cancer patient profiling tool to improve physician-patient communication. an analysis in breast cancer patients 149
4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study 148
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) 148
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs 147
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare 146
Are all cyclin-dependent kinases 4/6 inhibitors created equal? 146
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 138
CDX-2 should be included in the work-up of patients with lung metastases from unknown primary 137
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes 137
"Burned out" phenomenon of the testis in retroperitoneal seminoma 133
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer 133
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer 133
Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain 132
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy 128
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter 124
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study 124
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial 121
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial 120
Antibody–drug conjugates in solid tumors: a look into novel targets 120
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib 118
Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer 117
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 117
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 116
Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma A C 116
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials 113
Immune approaches to the treatment of breast cancer, around the corner? 113
Edoxaban for Cancer-Associated Venous Thromboembolism 112
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 110
Talking to patients about biosimilars 110
Dendritic cell sarcoma : an analytic overview of the literature and presentation of original five cases 109
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic : An International Collaborative Group 109
Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an "innocent bystander" 108
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors 108
Locoregional recurrence risk after lipofilling in breast cancer patients 107
Radioterapia trifrazionata (trt)e chemioterapia di induzione (ict) nei tumori polmonari non microcitomi ( nsclc) localmente avanzati: risultati preliminari 106
Impact of autoimmune diseases on outcome of patients with early breast cancer 105
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives 105
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 105
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer : a retrospective multicenter study 105
Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer 104
Is explanation a marketing problem? The quest for trust in artificial intelligence and two conflicting solutions 104
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 103
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients 103
RNAi screens identify CHD4 as an essential gene in breast cancer growth 103
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients 102
Lessons from the first ecancer symposium on angiogenesis in gastric cancer 102
Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study 101
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 101
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas 101
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers 101
Lucitanib for the treatment of HRþ/HER2- Metastatic breast cancer : Results from the multicohort phase II FINESSE study 101
Nipple-sparing mastectomy--is it worth the risk? 100
QTc prolongation assessment in anticancer drug development : clinical and methodological issues 98
Totale 23576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71990
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71990
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018110 0000 00 00 000110
2018/20194116 630224452311 146296 445151 312242468439
2019/20207885 941410607930 625942 719466 779790362314
2020/20218837 408400506432 750891 497555 129982711701102
2021/20228823 727770629613 761663 781599 9075865391248
2022/20238766 1098715975716 8941503 365600 84232867456
Totale 42150